Takeda Pharmaceuticals has successfully acquired the intellectual property rights for the Vitrum vitamin brand from Unipharm Inc., enhancing its market position in the Russian pharmaceutical sector.
Target Information
On September 1, 2017, Takeda Pharmaceuticals (TYO: 4502), a prominent pharmaceutical company headquartered in Japan, finalized the acquisition of intellectual property rights for several over-the-counter (OTC) and food supplement (FS) products from Unipharm Inc. (USA). This acquisition includes global rights to the renowned Vitrum vitamin brand, solidifying Takeda's presence in the marketing of health supplements.
The Vitrum brand is a market leader in the Russian multivitamin sector, with retail sales exceeding 3 billion RUB (approximately 50 million USD) in 2016 according to IMS Health data. This acquisition is a strategic move for Takeda, reinforcing its market position in Russia and the Commonwealth of Independent States (CIS).
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview in Russia
The Russian pharmaceutical industry is characterized by its significant growth potential and strong market demand for health-related products. Factors such as an aging population, increasing health awareness, and risi
Similar Deals
Penta Hospitals → Group Mediterra, a.s.
2025
Takeda Pharmaceuticals
invested in
Unipharm Inc.
in 2017
in a Merger deal
Disclosed details
Revenue: $50M